RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
Author:
Open Access
- 23 April 2019
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 8, 533
Abstract
Although remarkable advances have been made in the treatment of rheumatoid arthritis (RA), novel therapeutic options with different mechanisms of action and fewer side effects have been expected. Recent studies have demonstrated that bone-resorbing osteoclasts are critically involved in the bone destruction associated with RA. Denosumab, a human antibody against receptor activator of nuclear factor-kappa B ligand (RANKL), efficiently suppressed the progression of bone erosion in patients with RA by suppressing osteoclast differentiation and activation in several clinical studies, although it had no effect on inflammation or cartilage destruction. Denosumab, in combination with anti-rheumatic drugs, is considered a pivotal therapeutic option for the prevention of bone destruction in RA.Keywords
This publication has 34 references indexed in Scilit:
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumabNature Reviews Drug Discovery, 2012
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17Rheumatology, 2008
- Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling systemImmunological Reviews, 2005
- Evolving concepts of rheumatoid arthritisNature, 2003
- Radiographic healing with sustained clinical remission in a patient with rheumatoid arthritis receiving methotrexate monotherapyArthritis & Rheumatism, 2002
- Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritisArthritis & Rheumatism, 2000
- A New Mechanism of Bone Destruction in Rheumatoid Arthritis: Synovial Fibroblasts Induce OsteoclastogenesisBiochemical and Biophysical Research Communications, 1997
- Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1989
- Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid jointArthritis & Rheumatism, 1984